Norway· NO-ID_C3DCB87B-6DD6-4DAC-8E02-D949F4E43329
Kisqali
A ribociclib product containing ribociclib, registered in Norway by Novartis Europharm Limited (1). The same ATC class is registered in 12 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Ribociclib is registered in 12 of 19 countries.
Countries holding a registration under ATC L01EF02 (ribociclib), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 8 of them publish a price we can compare per daily dose
Ribociclib · ATC L01EF02
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ribociclib costs, country by country.
Normalised to the WHO defined daily dose (0.45 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ribociclib · price per daily dose (0.45 g)
USD · FX 28 Sept 2026
- CH Switzerland$111.31
The record
At a glance
FEST (Norway)- Active substance
- Ribociclib
- Manufacturer
- Novartis Europharm Limited (1)
- Country
- Norway (NO)
- ATC code
- L01EF02
- ATC class
- Ribociclib
- Defined daily dose
- 0.45 g, O
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 13
6 priced- gtin7613421228484
- gtin7613421228477
- gtin7613421188580
- gtin7613421188337
- gtin7613421188344
- no_varenummer18348521NOK 17772
- no_merkevare_idID_C3DCB87B-6DD6-4DAC-8E02-D949F4E43329
- no_varenummer50126321NOK 17772
- no_varenummer44988363NOK 53243.5
- no_varenummer40871942NOK 35509.1
- no_varenummer10778542NOK 35509.1
- no_varenummer53979363NOK 53246.2
- gtin7613421228460
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
679 interactions on record for ribociclib.
Graded by severity as the source publishes them — 315 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ribociclib · interactions on record
679 records
- 315 severe
- 347 moderate
- 17 minor
Most severe, free to view
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- DolasetronA04AA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ribociclib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaKISQALINovartis Europharm Limited, Dublin
- United StatesKISQALINovartis Pharmaceuticals Corporation
- SpainKISQALI 200 MG COMPRIMIDOS RECUBIERTOS CON PELICULANovartis Europharm Limited
- BelgiumKisqali 200 mgNovartis Europharm
- IcelandKisqaliNovartis Europharm Limited*
- NetherlandsKisqali 200 mg filmomhulde tablettenNovartis Europharm Limited
- PolandKisqaliNovartis Europharm Limited
- SwedenKisqali 200 mg Filmdragerad tablettNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Kisqali
- Liechtenstein · Kisqali
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/727b34e8-bc89-4072-9ee8-ac3340c57d89 GET /v1/drugs/727b34e8-bc89-4072-9ee8-ac3340c57d89?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablett, filmdrasjert",
"source": "fest",
"status": "A",
"atc_name": "Ribosiklib",
"merkevare_id": "ID_C3DCB87B-6DD6-4DAC-8E02-D949F4E43329",
"name_form_strength": "Kisqali tab 200 mg",
"prescription_group": "C"
}See everything about ribociclib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.